This article is for general informational purposes only and is not legal advice; all settlement figures reflect 2026 data from the proposed Monsanto class settlement and named primary sources, and remain subject to court approval and change.
TL;DR — Quick Verdict
- Bayer’s proposed $7.25 billion class settlement would pay qualifying non-Hodgkin lymphoma (NHL) claimants standard awards of $10,000 to $165,000, with occupational claims reaching roughly $198,000 after adjustments.
- The settlement is not yet final — a Missouri court granted preliminary approval on March 4, 2026, and the fairness hearing was rescheduled to August 19, 2026.
- Residential (home-use) claimants average $20,000–$40,000; occupational claimants average $60,000–$165,000 — a gap of more than 4x driven by exposure type.
- The Supreme Court’s June 25, 2026 7–2 ruling in Monsanto v. Durnell preempts most state failure-to-warn claims, weakening the leverage of claimants who opt out.
- After a typical 33%–40% contingency fee, a $100,000 gross award nets roughly $60,000–$67,000 before liens.
- Recommendation: Most current claimants are better off staying in the settlement than pursuing an individual suit post-Durnell — but confirm your tier before accepting a Quick-Pay offer.
More than 170,000 people have filed Roundup cancer claims against Bayer and its Monsanto subsidiary — one of the largest mass tort dockets in American history, according to figures reported by Sokolove Law as of August 2026. In February 2026, Bayer proposed a $7.25 billion class settlement to resolve current and future non-Hodgkin lymphoma claims tied to the glyphosate-based weed killer. Days later, its stock fell roughly 10% as investors absorbed the added liability, per reporting from OpenClassActions.
The money is real, but it is neither final nor evenly distributed. A home gardener diagnosed at 79 and a full-time landscaper diagnosed at 52 fall into wildly different payout tiers. This article breaks down the verified payout ranges, the nine-tier scoring system, the deadlines that govern your claim, and how the Supreme Court’s Durnell decision reshapes your options. You will see the actual dollar figures, the math behind net recovery after attorney fees, and a direct comparison of staying in the settlement versus filing individually.
Roundup Settlement Payout Amounts by Tier in 2026
Payouts hinge on one primary split: where you were exposed. Occupational users — farmers, landscapers, groundskeepers — sit in the top tiers. Residential users who sprayed their own yards land lower. The settlement administrator, BrownGreer PLC, assigns each claimant to one of nine tiers based on exposure type, age at diagnosis, and whether the NHL is fast- or slow-growing.
Source: OpenClassActions settlement analysis and The Hill reporting on the proposed Monsanto class settlement, 2026 (verify at thehill.com).
Scoring can move a final gross payment between roughly 80% and 120% of the applicable tier average, per settlement documentation summarized by tuccsettlement.com. That means the “$165,000” you may see advertised is a ceiling for a specific profile — not a default. Understanding how these mass tort attorney fee structures reduce your take-home is essential before you sign anything.
What Determines Your Roundup Payout: The Nine-Tier Scoring System
Consider two real-world profiles. A 52-year-old commercial landscaper with 20 years of documented daily Roundup use and diffuse large B-cell lymphoma (an aggressive subtype) scores near the top. He needs employment records, tax documents, and pathology reports — but his projected award sits in the $150,000–$165,000 band, potentially higher with adjustments.
Now take a 79-year-old retiree who sprayed Roundup on a home garden for a decade and was recently diagnosed with a slow-growing follicular lymphoma. Age places her in tier nine automatically. Her sworn statement of exposure is enough — no documentary proof required — but her Quick-Pay award may land between $6,000 and $14,500.
Four factors drive the score after tier assignment: treatment received (chemotherapy, stem-cell transplant), strength of exposure proof, duration and frequency of use, and NHL subtype. The system mirrors the tiered point structure Bayer used in its 2020 program, where claims administrators divided the pool by each case’s point value. Claimants weighing whether the structured program fits their situation should understand how mass tort and class action payouts differ, because this settlement blends features of both.
Settlement Status and Deadlines: Where Things Stand in 2026
Timing matters as much as tier. The proposed settlement has cleared preliminary approval but is not yet paying program awards. Missing a deadline can forfeit a claim entirely.
Source: OpenClassActions and ConsumerShield settlement trackers, 2026 (verify at consumershield.com).
Claims registration and submission open only after final approval. The first $1 billion is front-loaded into year one, with the balance paid over 17 to 21 years. For a broader view of how these phases unfold, see this breakdown of mass tort case timelines by litigation stage. Anyone contacted by a solicitor promising an immediate check should review guidance on verifying mass tort claims and avoiding scams before sharing personal information.
How the Supreme Court’s Durnell Ruling Changes Everything
On June 25, 2026, the U.S. Supreme Court ruled 7–2 in Monsanto Co. v. Durnell that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state-law failure-to-warn claims when the EPA has determined a cancer warning is not required. The decision, documented by Cornell’s Legal Information Institute and analyzed by Holland & Knight, reversed a $1.25 million Missouri verdict and foreclosed the legal theory behind the vast majority of Roundup claims.
Bayer said it expects the ruling to “significantly contain” the litigation. That is not corporate spin — failure-to-warn was the backbone of most cases. But Durnell is not a total shield. Legal analysts at Crowell & Moring note that design-defect, manufacturing-defect, negligent-testing, fraud, and advertising claims may survive, depending on state law and the facts.
The practical effect: claimants who opted out to pursue individual suits now face a far weaker legal position on the most common claim type. The settlement’s value proposition — guaranteed structured payment versus uncertain, preempted litigation — strengthened overnight.
Stay in the Settlement vs. File Individually: Which Is Better After Durnell?
Before Durnell, an individual suit carried real upside. Juries had delivered staggering verdicts: a $2.1 billion Georgia award in 2025, a $332 million California verdict in 2023, and a $2.25 billion consolidated verdict, per OpenClassActions. Many were reduced on appeal, but the leverage was undeniable.
After Durnell, that leverage collapsed for failure-to-warn claims. An individual plaintiff must now build a case on surviving theories — harder, slower, and more expensive. The settlement offers a defined tier, a sworn-statement path for residential claimants, and Quick-Pay for lower tiers.
Verdict
For the overwhelming majority of current claimants whose cases rest on failure-to-warn, staying in the $7.25 billion settlement is the stronger move after Durnell. The guaranteed structured award — even at $20,000–$40,000 for residential users — now outweighs individual litigation that the Supreme Court has largely preempted. The exception: claimants with strong design-defect or fraud evidence, aggressive cancer, and documented occupational exposure, who should get an individual case evaluation before accepting any tier assignment.
What Most People Get Wrong About the Roundup Settlement
Three mistakes repeatedly cost claimants money.
Mistake 1: Assuming everyone gets $165,000
That figure is the occupational ceiling for a young claimant with aggressive NHL and documented work exposure. Consequence: residential claimants expecting six figures reject fair $30,000 offers and stall their claims. Correct action: identify your tier using exposure type and age before evaluating any number.
Mistake 2: Grabbing Quick-Pay without checking the program award
Quick-Pay ($6,000–$14,500) pays fast on a first-in, first-out basis, but program awards are larger. Consequence: a claimant who could qualify for a $40,000 residential program award accepts $12,000 for speed. Correct action: compare both paths in writing before signing.
Mistake 3: Ignoring healthcare liens
Medicare, Medicaid, and private insurers can claw back treatment costs from your award. Consequence: a claimant nets far less than the tier figure suggests. Correct action: resolve liens as part of the settlement process, and factor them alongside the contingency fee that reduces net recovery.
Is the Roundup Settlement Worth It? Who Should File
Run the math. A $100,000 gross occupational award, minus a 35% contingency fee, leaves $65,000 before liens. If Medicare asserts a $15,000 lien, the claimant nets roughly $50,000. That framework — gross award, minus fee, minus liens — applies to every tier.
You should file if you have a confirmed NHL diagnosis (including B-cell or T-cell subtypes) and any documented Roundup exposure, occupational or residential. Future filers count too: people diagnosed later can claim within the settlement’s forward-looking window, reported as up to 16 years from final approval by Sokolove Law. Deceased victims’ estates may also file through executors.
You should think harder if you opted out and your case rests solely on failure-to-warn — Durnell has likely foreclosed it. The litigation compares instructively to other pending mass torts; those weighing multiple potential claims can review parallel dockets like the paraquat Parkinson’s lawsuit outlook and the talcum powder settlement deadlines to understand how tiered compensation programs typically resolve.
Frequently Asked Questions
How much is the average Roundup settlement payout in 2026?
Standard awards under the proposed $7.25 billion settlement range from $10,000 to $165,000, per The Hill and OpenClassActions reporting. Residential (home-use) claimants average $20,000–$40,000, while occupational claimants average $60,000–$165,000. Scoring can adjust the final gross payment between roughly 80% and 120% of the applicable tier average, and occupational awards can reach about $198,000 with adjustments.
Is the Roundup settlement finalized?
No. The Missouri 22nd Judicial Circuit Court granted preliminary approval on March 4, 2026, but the fairness hearing was rescheduled to August 19, 2026. Claims registration and submission open only after final approval. Until then, no program awards are being paid, though Quick-Pay awards for lower tiers may begin on a first-in, first-out basis, according to settlement administrators cited by OpenClassActions.
How did the Supreme Court’s Durnell decision affect my claim?
The June 25, 2026 ruling in Monsanto v. Durnell (7–2) held that FIFRA preempts state-law failure-to-warn claims, per Cornell’s Legal Information Institute. This foreclosed the most common Roundup legal theory and reversed a $1.25 million verdict. Claimants inside the settlement are largely unaffected; those who opted out to pursue failure-to-warn suits now face a substantially weaker position.
How much will attorney fees reduce my Roundup payout?
Contingency fees in mass tort cases typically run 33% to 40%, per Lawfold’s analysis of prior Roundup settlements. On a $100,000 gross award, that leaves $60,000–$67,000 before healthcare liens from Medicare, Medicaid, or private insurers are deducted. Always confirm the fee percentage and lien exposure in writing before accepting a tier assignment or Quick-Pay offer.
How We Researched This Article
This analysis draws exclusively on primary and named institutional sources documenting the Roundup litigation and the proposed 2026 class settlement. Court records and the settlement structure were verified against the U.S. Supreme Court’s decision in Monsanto Co. v. Durnell, No. 24-1068, as published by Cornell Law School’s Legal Information Institute (law.cornell.edu), and cross-checked against legal analyses from Holland & Knight (hklaw.com) and Stanford Law School’s Legal Aggregate (law.stanford.edu).
Payout tiers, eligibility criteria, and deadlines were compiled from settlement tracking by The Hill (thehill.com) and OpenClassActions, with corroborating figures from ConsumerShield and Sokolove Law. Historical settlement context, including the 2020 $10.9 billion agreement covering roughly 125,000 claims, was verified against Bayer’s own corporate disclosures via BusinessWire.
Where sources reported conflicting totals for Bayer’s cumulative Roundup spending — figures ranged from approximately $11 billion to $16 billion depending on whether reserves and future provisions were included — we report the range and its cause rather than a single point figure. All payout figures reflect the proposed settlement and remain subject to court approval; modeled net-recovery examples (gross award minus fee minus lien) are illustrative calculations, not measured averages. This research was last conducted in August 2026. All figures were verified against named primary sources before publication.